Nikolaos Tsesmetzis

Karolinska Institutet — Sweden

Medicine · Health Sciences

9h-index587citations18works3.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(8), Chronic Lymphocytic Leukemia Research(5), Cancer Immunotherapy and Biomarkers(3), Acute Myeloid Leukemia Research(3), RNA Research and Splicing(2)

Publications18 total

Targeting IMPDH to inhibit SAMHD1 in <i>KMT2A</i> -rearranged leukaemia
Cell Cycle·2025Open Access
Addition of hydroxyurea (hydroxycarbamide) enhances the efficacy of fludarabine/cytarabine‐based salvage regimens against acute myeloid leukaemia
British Journal of Haematology·2025· 1 citedOpen Access
SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma
Blood·2024· 11 citedOpen Access
SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma.
PubMed·2024
Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial
Journal of Internal Medicine·2022· 17 citedOpen Access
ALK+ Anaplastic Large Cell Lymphoma (ALCL)-Derived Exosomes Carry ALK Signaling Proteins and Interact with Tumor Microenvironment
Cancers·2022· 6 citedOpen Access
Ribonucleotide reductase inhibitors suppress <scp>SAMHD</scp> 1 ara‐ <scp>CTP</scp> ase activity enhancing cytarabine efficacy
EMBO Molecular Medicine·2020· 57 citedOpen Access
ALK+ Anaplastic Large Cell Lymphoma (ALCL)-Derived Exosomes Carry ALK Signalling Proteins and Interact With Tumor Microenvironment
Research Square (Research Square)·2020Open Access
STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer
Cancers·2019· 93 citedOpen Access
The Novel Tumor Suppressor SAMHD1 Is Differentially Expressed and Partly Regulated By MYC in Peripheral T-Cell Lymphomas (PTCL)
Blood·2018· 1 cited
Genetic Basis, Expression Patterns and Clinical Significance of PD-L1 in Peripheral T-Cell Lymphomas (PTCL)
Blood·2018· 1 cited
Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens
Blood Cancer Journal·2018· 42 citedOpen Access
Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism
Cancers·2018· 132 citedOpen Access
Downregulation of the Tumor Suppressor SAMHD1 in Classical Hodgkin Lymphoma
Blood·2017· 1 cited
Regulation of PD-L1 in breast cancer.
Journal of Clinical Oncology·2017· 2 cited
PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma
Leukemia·2017· 188 cited
<scp>CD</scp>274 (<scp>PD</scp>‐L1)/<scp>PDCD</scp>1 (<scp>PD</scp>‐1) expression in de novo and transformed diffuse large B‐cell lymphoma
British Journal of Haematology·2016· 26 citedOpen Access
Potential role of AKT/mTOR signalling proteins in hairy cell leukaemia: association with BRAF/ERK activation and clinical outcome
Scientific Reports·2016· 9 citedOpen Access

Frequent Co-authors

Nikolas Herold(10), George Z. Rassidakis(9), Georgios Z. Rassidakis(7), Sijia Tao(5), Raymond F. Schinazi(5), Baek Kim(5), Ingrid Lilienthal(5), Ηλίας Δράκος(4), Sean G. Rudd(4), Ioanna Xagoraris(4), Vasiliki Leventaki(3), Theocharis Panaretakis(3), Janne Lehtiö(3), Sören Lehmann(3), Jan‐Inge Henter(3), Torsten Schaller(3), Martin Jädersten(3), Sofia Bengtzén(3), Anna Bohlin(3), Agata M. Wasik(3)